KB-1303

L2K-hIgG1

45461

Background of L2K-hIgG1

L2K is a humanized monoclonal antibody derived from OKT3, which reacts with an epitope on the epsilon-subunit within the human CD3 complex, and have potent immunosuppressive properties in vivo and has been proven effective in the treatment of renal, heart and liver allograft rejection. L2K sequence was widely used in many bispecific antibodies against both of the tumor associated antigen and CD3e.

Specifications

Catalog Number	KB-1303
Antibody Name	L2K-hIgG1
Isotype	Human IgG1,kappa
Target	CD3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS \| Activation
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Pauline Wimberger Wei Xiang &Doris Mayr et al. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. IJC. Volume105, Issue2(2003).